Literature DB >> 26620376

Spectrum and treatment of anaerobic infections.

Itzhak Brook1.   

Abstract

Anaerobes are the most predominant components of the normal human skin and mucous membranes bacterial flora, and are a frequent cause of endogenous bacterial infections. Anaerobic infections can occur in all body locations: the central nervous system, oral cavity, head and neck, chest, abdomen, pelvis, skin, and soft tissues. Treatment of anaerobic infection is complicated by their slow growth in culture, by their polymicrobial nature and by their growing resistance to antimicrobials. Antimicrobial therapy is frequently the only form of therapy needed, whereas in others it is an important adjunct to drainage and surgery. Because anaerobes generally are isolated mixed with aerobes, the antimicrobial chosen should provide for adequate coverage of both. The most effective antimicrobials against anaerobes are: metronidazole, the carbapenems (imipenem, meropenem, doripenem, ertapenem), chloramphenicol, the combinations of a penicillin and a beta-lactamase inhibitors (ampicillin or ticarcillin plus clavulanate, amoxicillin plus sulbactam, piperacillin plus tazobactam), tigecycline, cefoxitin and clindamycin.
Copyright © 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anaerobes; Antibiotics; Antimicrobial resistance; Bacteroides fragilis; Infection

Mesh:

Substances:

Year:  2015        PMID: 26620376     DOI: 10.1016/j.jiac.2015.10.010

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  20 in total

1.  Prognostic Indicators of Recurrence of Bacterial Vaginosis.

Authors:  Jack D Sobel; Navkiranjot Kaur; Nicole A Woznicki; Dina Boikov; Tina Aguin; Gurveer Gill; Robert A Akins
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

2.  Protection from doxorubicin-induced nephrotoxicity by clindamycin: novel antioxidant, anti-inflammatory and anti-apoptotic roles.

Authors:  Kamilia M Ibrahim; Eman M Mantawy; Mona M Elanany; Hend S Abdelgawad; Nuha M Khalifa; Rada H Hussien; Nermeen N El-Agroudy; Ebtehal El-Demerdash
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

3.  Protective Effect of a Synbiotic against Multidrug-Resistant Acinetobacter baumannii in a Murine Infection Model.

Authors:  Takashi Asahara; Akira Takahashi; Norikatsu Yuki; Rumi Kaji; Takuya Takahashi; Koji Nomoto
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Surveillance of Antimicrobial Susceptibility of Anaerobe Clinical Isolates in Southeast Austria: Bacteroides fragilis Group Is on the Fast Track to Resistance.

Authors:  Elisabeth König; Hans P Ziegler; Julia Tribus; Andrea J Grisold; Gebhard Feierl; Eva Leitner
Journal:  Antibiotics (Basel)       Date:  2021-04-21

5.  What we actually know about the pathogenicity of Bacteroides pyogenes.

Authors:  Anna Majewska; Marta Kierzkowska; Dariusz Kawecki
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

6.  Exploratory Investigation of Bacteroides fragilis Transcriptional Response during In vitro Exposure to Subinhibitory Concentration of Metronidazole.

Authors:  Michele C R de Freitas; Juliana A Resende; Alessandra B Ferreira-Machado; Guadalupe D R Q Saji; Ana T R de Vasconcelos; Vânia L da Silva; Marisa F Nicolás; Cláudio G Diniz
Journal:  Front Microbiol       Date:  2016-09-20       Impact factor: 5.640

7.  Notes from the Field: Veillonella Misidentified as Francisella tularensis - Idaho, 2016.

Authors:  Kris K Carter; Erin M Peterson; Robert L Voermans; Kenneth S Anderson; Tamara Cox; Ahmed M Kassem; Christopher L Ball; Christine G Hahn
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-06-02       Impact factor: 17.586

8.  In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria.

Authors:  Laure Stapert; Cindy Wolfe; Dean Shinabarger; Andrea Marra; Chris Pillar
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.

Authors:  Lauren M Castner; Madsen Zimbric; Shannon Cahalan; Corey Powell; Lindsay J Caverly
Journal:  J Cyst Fibros       Date:  2021-02-19       Impact factor: 5.482

10.  Use of Meropenem in a Tertiary Pediatric Hospital in Costa Rica and Its Role in the Era of Antimicrobial Stewardship.

Authors:  Constanza Chacón-González; Daniel Rivera-Salgado; Helena Brenes-Chacón; Gabriela Naranjo-Zuñiga; María L Ávila-Aguero
Journal:  Cureus       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.